Morningstar

Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the ...
ksn.com

U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus

"The physical, emotional, and economic burden of a curable condition like hepatitis C is far too great in the United States and around the world," said John Ward, M.D., director, Coalition for Global ...
Healio

Mavyret approved for acute HCV

Please provide your email address to receive an email when new articles are posted on . The approval allows for immediate treatment following diagnosis. Patients treated in a phase 3 study experienced ...
Insider Monkey

AbbVie (ABBV) Pipeline Bolstered as FDA Approves Mavyret Label Expansion for Hepatitis C

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion. The approval ...
Insider Monkey

AbbVie Secures FDA Approval to Expand Mavyret’s Label

AbbVie Inc. (NYSE:ABBV) is one of the best stocks for a dividend stock portfolio. The company announced that the US FDA has expanded the approved use of its oral antiviral drug Mavyret, developed in ...
Nasdaq

U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus

NORTH CHICAGO, Ill., June 11, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for ...